Invesco
ADVM

Invesco’s Adverum Biotechnologies ADVM Stock Holding History

Invesco’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,831
Closed -$218K – 3762
2025
Q1 		$218K Buy
+49,831
New +$225K ﹤0.01% 3483
2023
Q1 		– Sell
-30,425
Closed -$176K – 3863
2022
Q4 		$176K Sell
30,425
-358
-1% -$2.71K ﹤0.01% 3721
2022
Q3 		$292K Sell
30,783
-1,726
-5% -$22.7K ﹤0.01% 3527
2022
Q2 		$390K Buy
32,509
+3,878
+14% +$40.6K ﹤0.01% 3455
2022
Q1 		$375K Buy
28,631
+26,021
+997% +$381K ﹤0.01% 3537
2021
Q4 		$46K Sell
2,610
-1,155
-31% -$23.1K ﹤0.01% 3986
2021
Q3 		$82K Sell
3,765
-196
-5% -$5K ﹤0.01% 3963
2021
Q2 		$138K Buy
3,961
+1,401
+55% +$75.5K ﹤0.01% 3848
2021
Q1 		$252K Sell
2,560
-293
-10% -$35.2K ﹤0.01% 3612
2020
Q4 		$310K Buy
2,853
+1,301
+84% +$161K ﹤0.01% 3404
2020
Q3 		$160K Sell
1,552
-39,338
-96% -$5.89M ﹤0.01% 3509
2020
Q2 		$8.54M Buy
40,890
+1,443
+4% +$256K ﹤0.01% 1729
2020
Q1 		$3.85M Buy
39,447
+22,686
+135% +$2.65M ﹤0.01% 2032
2019
Q4 		$1.93M Buy
16,761
+11,345
+209% +$1,000K ﹤0.01% 2662
2019
Q3 		$296K Sell
5,416
-24,316
-82% -$2.74M ﹤0.01% 3431
2019
Q2 		$3.54M Buy
29,732
+24,691
+490% +$2.04M ﹤0.01% 2391
2019
Q1 		$264K Buy
5,041
+360
+8% +$14.6K ﹤0.01% 3538
2018
Q4 		$147K Buy
4,681
+648
+16% +$26.4K ﹤0.01% 3601
2018
Q3 		$244K Buy
4,033
+120
+3% +$6.74K ﹤0.01% 3650
2018
Q2 		$207K Sell
3,913
-3,392
-46% -$204K ﹤0.01% 3694
2018
Q1 		$424K Buy
+7,305
New +$455K ﹤0.01% 3392
2015
Q3 		– Sell
-39,096
Closed -$6.35M – 3784
2015
Q2 		$6.35M Buy
39,096
+34
+0.1% +$11.5K ﹤0.01% 1802
2015
Q1 		$15.8M Buy
+39,062
New +$16.5M 0.01% 1321

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco's ADVM Position: Q2 2025 in Review

Invesco sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 49,831 shares — an estimated $218K sold.

Invesco first reported a position in ADVM in Q1 2015 and held it in 23 quarters. The position peaked at $15.8M in Q1 2015. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.

  • Invesco reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Invesco sold 49,831 Adverum Biotechnologies shares in Q2 2025, an estimated $218K.
  • Invesco first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 23 quarters.
  • Invesco's Adverum Biotechnologies position peaked at $15.8M in Q1 2015.
  • 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.